CTRI/2021/02/031295已完成1 期
A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 175
- 试验地点
- 4
- 主要终点
- 1.To evaluate the reactogenicity and safety of BBV154 (Adenoviral vectored based SARS-CoV-2 virus) vaccine administered via the intranasal route.
研究概览
简要总结
Protocol Title: A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine(BBV154) in Healthy Volunteers.
The study is designed to evaluate the safety, reactogenicity, and immunogenicity of three groups of healthy volunteers who receive either intranasal single dose (Vaccine on Day 0 and placebo on Day 28) or two-dose (vaccine on Day 0 and 28) of BBV154 vaccine or Placebo (on Day 0 and day 28).
A total of 175 subjects will be enrolled in 2:2:1 ratio and will be conducted in a double-blinded manner.
Group 1 (Single dose group): In this group, 70 participants will be recruited and administered with the vaccine (BBV154) on day 0 and with placebo on day 28 via the intranasal route.
Group 2 (Two-dose group): In this group, 70 participants will be recruited and administered with the vaccine (BBV154) on both day 0 and on day 28 via the intranasal route.
Group 3 (Placebo): In this group, 35 participants will be recruited and administered with placebo on both day 0 and day 28 via the intranasal route.
Data will be un-blinded to the third-party bio-statistician and an interim analysis will be performed at day 42 for Immunogenicity, Safety and submitted to CDSCO.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Ability to provide written informed consent.
- •Participants of either gender of age between ≥18 to ≤60 years.
- •Good general health as determined by the discretion of investigator (vital signs (heart rate ≥60 to≤100 bpm; blood pressure systolic ≥90 mm Hg and <140 mm Hg; diastolic ≥ 60 mm Hg and <90 mm Hg; oral temperature <100.4ºF), medical history, and physical examination).
- •Expressed interest and availability to fulfil the study requirements.
- •For a female participant of child-bearing potential, planning to avoid becoming pregnant (use of an effective method of contraception or abstinence) from the time of study enrolment until at least four weeks after the last vaccination.
- •Male subjects of reproductive potential: Use of condoms to ensure effective contraception with the female partner from first vaccination until 3 months after last vaccination.
- •Male subjects agree to refrain from sperm donation from the time of first vaccination until 3 months after last vaccination.
- •Participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination.
- •Agrees not to participate in another clinical trial at any time during the study.
- •Agrees to remain in the study area for the entire duration of the study.
- •Willing to allow storage and future use of biological samples for future research.
排除标准
- •1.History of any other COVID-19 investigational/or licensed vaccination.
- •2.Unacceptable laboratory abnormality at screening (prior to first vaccination) or safety testing, as listed below 3.[Abnormal Complete Blood Count (CBC), Random blood sugar level, Renal function test (serum urea and Creatinine), liver function tests, urine analysis report, Positive serology for hepatitis C or HIV antibody or hepatitis B surface antigen] (Subjects will be informed if their results are positive for hepatitis C, HIV 1 & 2 antibody or hepatitis B surface antigen (HBsAg) and will be referred to a primary care provider for follow up of these abnormal laboratory tests).
- •4.Confirmed SARS-CoV-2 at the time of screening using RT-PCR and ELISA or CLIA method.
- •5.Any history of facial nerve paralysis 6.History of cold, sneezing, nasal obstruction in the past 3 days.
- •7.Prescribed usage of any nasal spray/or nasal drop medication.
- •8.Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month are excluded) 9.For women of child bearing potential, a positive serum pregnancy test (during screening within 45 days of enrolment) or positive urine pregnancy test (within 24 hours of administering each dose of vaccine).
- •10.Temperature >38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an upper respiratory infection or gastroenteritis within three days prior to each dose of vaccine.
- •11.Medical problems as a result of alcohol or illicit drug use during the past 12 months.
- •12.Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before enrolment or expects to receive an investigational agent during the study period.
- •13.Receipt of any licensed vaccine within four weeks before enrolment in this study.
- •14.Known sensitivity to any ingredient of the study vaccines, or a more severe allergic reaction and history of allergies in the past.
- •15.Receipt of immunoglobulin or other blood products within the three months prior to vaccination in this study.
- •16.Immunosuppression as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy within the preceding 36 months.
- •17.Long-term use (> 2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding six months (nasal and topical steroids are allowed).
- •18.Any history of hereditary angioedema or idiopathic angioedema.
- •19.Any history of anaphylaxis in relation to vaccination.
- •20.Any history of albumin-intolerance.
- •22.History of any cancer.
- •23.History of severe psychiatric severe conditions likely to affect participation in the study.
- •24.A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or prior history of significant bleeding or bruising following IM injections or venepuncture.
- •25.Any other serious chronic illness requiring hospital specialist supervision.
- •26.Chronic respiratory diseases like severe acute respiratory syndrome (SARS), including mild asthma.
- •27.Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness 28.Morbidly obese (BMI≥35 kg/m2) or underweight (BMI ≤18 kg/m2).
- •29.Living in the same household of any COVID-19 positive person.
- •30.Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.
- •Re-Vaccination Exclusion Criteria 31.Pregnancy.
- •32.Anaphylactic reaction following administration of the investigational vaccine.
- •33.Virologically confirmed cases SARS-CoV-2 infection.
结局指标
主要结局
1.To evaluate the reactogenicity and safety of BBV154 (Adenoviral vectored based SARS-CoV-2 virus) vaccine administered via the intranasal route.
时间窗: Baseline, Day 28 [Time Frame: within 2 hours post each vaccination] | [Time Frame: 7 days]. | The occurrence of serious adverse events (SAEs) [Time Frame: throughout the study duration]. | The occurrence of any unsolicited adverse events up to day 35 from 1st dose vaccination. [Time Frame: up to day 35 from 1st dose vaccination].
次要结局
- 1.To evaluate the humoral immune responses of BBV154.(2.To compare the humoral responses between single dose group and double dose group.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
4 期
A Post licensure clinical study to compare and evaluate safety, reactogenicity and Lot-to-Lot consistency of three production batches of liquid pentavalent DTwP-rHepB-HIB vaccine manufactured by BE LTD in healthy 6 to 8 week old infants.CTRI/2011/04/001675Biological E Limited660
终止
1 期
A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60Postoperative Wound Infection-deepPost Operative Wound InfectionNCT02280395Pulmatrix Inc.9
已完成
1 期
A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese SubjectsHealthy Male VolunteersNCT04467060Sihuan Pharmaceutical Holdings Group Ltd.74
已完成
1 期
Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940Low Back PainNCT00689780AstraZeneca60
已完成
1 期
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type PsoriasisPsoriasisNCT03337022Celgene34